Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis.
Dolman KM, Stegeman CA, van de Wiel BA, Hack CE, von dem Borne AE, Kallenberg CG, Goldschmeding R. Dolman KM, et al. Among authors: van de wiel ba. Clin Exp Immunol. 1993 Sep;93(3):405-10. doi: 10.1111/j.1365-2249.1993.tb08192.x. Clin Exp Immunol. 1993. PMID: 8370167 Free PMC article.
Complement and antibody enhance binding and uptake of HIV-1 by bone marrow cells.
van de Wiel BA, Bakker LJ, de Graaf L, de Weger RA, Verhoef J, van den Tweel JG, Joling P. van de Wiel BA, et al. Among authors: van den tweel jg, de graaf l, de weger ra. Adv Exp Med Biol. 1994;355:159-63. doi: 10.1007/978-1-4615-2492-2_27. Adv Exp Med Biol. 1994. PMID: 7535972 No abstract available.
Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM. Tjin EP, et al. Among authors: van de wiel ba, van de kasteele w. Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10. Cancer Immunol Res. 2014. PMID: 24894091
Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM; REPOSIT study group. van der Hiel B, et al. Among authors: van de wiel ba, van den eertwegh ajm. BMC Cancer. 2017 Sep 15;17(1):649. doi: 10.1186/s12885-017-3626-5. BMC Cancer. 2017. PMID: 28915798 Free PMC article.
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).
Rozeman EA, Prevoo W, Meier MAJ, Sikorska K, Van TM, van de Wiel BA, van der Wal JE, Mallo HA, Grijpink-Ongering LG, Broeks A, Lalezari F, Reeves J, Warren S, van Thienen JV, van Tinteren H, Haanen JBAG, Kapiteijn E, Blank CU. Rozeman EA, et al. Among authors: van de wiel ba, van tm, van thienen jv, van der wal je, van tinteren h. Melanoma Res. 2020 Jun;30(3):252-260. doi: 10.1097/CMR.0000000000000653. Melanoma Res. 2020. PMID: 31895753 Clinical Trial.
58 results